Stroke is a leading cause of death and long-term disability worldwide. Despite substantial advances in acute stroke care, there remains a lack of evidence-based digital solutions to support patients after hospital discharge. This study evaluates the effectiveness of a digital health application (StrokeApp) designed to support patients with ischemic or hemorrhagic stroke or transient ischemic attack (TIA) in secondary prevention and recovery. In this multicenter, randomized, controlled, open-label trial, 500 patients will be assigned in a 1:1 ratio to receive either standard care alone or standard care in combination with StrokeApp. The primary objective is to assess the impact of the application on health-related quality of life three months after discharge. Secondary and exploratory outcomes include health literacy, medication adherence, vascular risk factors, health-related behaviors, psychosocial outcomes, long-term recovery up to twelve months, as well as safety and user experience.
This study evaluates the clinical effectiveness, usability, and safety of a digital health application (StrokeApp) designed to support patients following ischemic stroke, hemorrhagic stroke, or transient ischemic attack (TIA) during the post-acute phase of care. The StrokeApp is a mobile medical application classified as a Class IIa medical device and is currently in the pivotal phase of clinical development. It is intended to complement standard care by supporting secondary prevention and self-management. Core functionalities include the provision of structured educational content, medication and appointment reminders, tools for documenting health-related parameters, and the collection of electronic patient-reported outcomes (ePROs). In addition, the application offers optional tracking features and automated feedback to support adherence to recommended health behaviors. The study is conducted as a multicenter, randomized, controlled, open-label clinical trial. Participants are enrolled during hospitalization for the index event and randomized in a 1:1 ratio to receive either standard care alone or standard care in combination with StrokeApp. The application is installed on the participant's personal mobile device during the hospital stay. Participants receive structured onboarding, including training on core functionalities and data entry. A reinforcement session is conducted prior to discharge to ensure independent use. Following discharge, participants in the intervention group use the application over a period of up to twelve months. During this time, they are prompted to complete ePROs at predefined intervals and may optionally use daily tracking functions. The application delivers reminders, educational material, and automated feedback based on user input. Technical support is available throughout the study period if needed. Study procedures and follow-up assessments are aligned with routine clinical practice. Data are collected through a combination of on-site visits, remote contacts, and electronic questionnaires. Participants in the control group follow the same visit schedule but complete patient-reported outcomes using web-based tools rather than the application. The study includes both short-term and long-term follow-up. Data collected during the study include patient-reported outcomes, clinical parameters obtained as part of routine care, and application usage data in the intervention group. Usage data include frequency of access, completion of questionnaires, and interaction with app features, enabling assessment of engagement and adherence. Safety is evaluated throughout the study by systematic documentation of adverse events and serious adverse events. Although the application is considered low risk, monitoring is performed to identify any potential unintended effects associated with its use, including issues related to usability, misunderstanding of content, or changes in healthcare utilization. In addition to patient-centered outcomes, the study includes an assessment of physician perspectives regarding the usability and perceived benefit of the application in routine care. This component aims to provide insights into the feasibility of integrating digital health applications into established clinical workflows. Overall, this study is designed to generate clinical evidence on the role of a digital health application in supporting post-stroke management under real-world conditions, including its integration into standard care pathways and its potential to support sustained patient engagement in secondary prevention.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
500
StrokeApp is a smartphone/tablet-based medical application designed to support patients following ischemic stroke, hemorrhagic stroke, or transient ischemic attack (TIA). The application is installed on the patient's personal device during hospitalization and includes structured onboarding. It provides educational content on stroke and secondary prevention, medication and appointment reminders, and tools for documenting health-related parameters. Patients complete electronic patient-reported outcomes (ePROs) at predefined time points. Optional daily tracking features and automated feedback support adherence to treatment recommendations and promote health-related behavior change. The application is used for up to 12 months in addition to standard care.
Standard post-stroke care according to clinical guidelines, including routine inpatient management and structured outpatient follow-up approximately three months after discharge. No digital application is provided.
University Hospital Tulln, Clinical Department of Neurology
Tulln, Lower Austria, Austria
St. John's Hospital, Vienna Department of Neurology
Vienna, State of Vienna, Austria
Medical University of Graz, Clinical Department of General Neurology
Graz, Styria, Austria
Medical University of Innsbruck, Department of Neurology
Innsbruck, Tyrol, Austria
Johannes Kepler University Linz, University Hospital for Neurology
Linz, Upper Austria, Austria
Pyhrn-Eisenwurzen Klinikum, Department of Neurology
Steyr, Upper Austria, Austria
Salzkammergut Klinikum Vöcklabruck, Department of Neurology
Vöcklabruck, Upper Austria, Austria
Health-related quality of life (EQ VAS)
Health-related quality of life measured using the EQ Visual Analogue Scale (EQ VAS), a standardized instrument assessing the participant's self-rated health on a scale from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: 3 months after hospital discharge
Health literacy (HLS19-Q12)
Time frame: Secondary outcome parameters will be assessed at 3 months.
The adherence to medication (MARS-D).
Time frame: Secondary outcome parameters will be assessed at 3 months.
Self-perceived stress (PPS-10)
Time frame: Secondary outcome parameters will be assessed at 3 months.
LDL-cholesterol levels
Time frame: Secondary outcome parameters will be assessed at 3 months.
HbA1c levels below 7.5% in patients with diabetes at baseline
Time frame: Secondary outcome parameters will be assessed at 3 months.
Average systolic office blood pressure level
Time frame: Secondary outcome parameters will be assessed at 3 months.
Physical activity (IPAQ)
Time frame: Secondary outcome parameters will be assessed at 3 months.
Number of cigarettes smoked per day
Time frame: Secondary outcome parameters will be assessed at 3 months.
Diet (MEPA)
Time frame: Secondary outcome parameters will be assessed at 3 months.
Alcohol consumption (AUDIT-C)
Time frame: Secondary outcome parameters will be assessed at 3 months.
Sleep quality (VAS)
Time frame: Secondary outcome parameters will be assessed at 3 months.
Average hours of sleep per night (self-reported)
Time frame: Secondary outcome parameters will be assessed at 3 months.
Symptoms of Anxiety (HADS-A)
Time frame: Secondary outcome parameters will be assessed at 3 months.
Symptoms of Depression (HADS-D)
Time frame: Secondary outcome parameters will be assessed at 3 months.
The patient's return to life after discharge (questionnaire) at 3 months.
Time frame: Secondary outcome parameters will be assessed at 3 months.
Fatigue (VAS)
Time frame: Secondary outcome parameters will be assessed at 3 months.
Overall quality of life (VAS)
Time frame: Secondary outcome parameters will be assessed at 3 months.
Health related quality of life (EQ-5D-3L overall health utility score calculated from individual 3-level components using rescaled European visual analogue scale weights)
Time frame: Secondary outcome parameters will be assessed at 3 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.